ClinicalTrials.gg
CompletedNCT02747004Next MONARCH 1Updated Oct 16, 2026Results posted

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

A Phase 2 interventional study of Abemaciclib and Tamoxifen in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 59 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
13th of 55
234 · median 120
Started
2016
with 4 others
Phase 2
27 of 55
12 open now
Registered
8th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 5 that started in 2016, is one of 27 in phase 2, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HR+, - breast cancer.
  • or progressed following endocrine therapy.
  • Have received prior treatment with at least 2 chemotherapy regimens, of which at least 1 but no more than 2 have been administered in the setting.
  • Have the presence of measureable disease as defined by the (RECIST 1.1).
  • Have a performance status ≤1 on the (ECOG) scale.
  • Have discontinued previous therapies for cancer (including specifically, aromatase inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy.
  • Have adequate organ function.
  • Have negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective precautions to prevent pregnancy during the study and for 3 weeks following last dose of study treatment.
  • Are able to swallow oral medication.

Exclusion criteria

Exclusion Criteria:

  • Have clinical evidence or history of central nervous system .
  • Have a personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
  • Have active bacterial or fungal infection (that is, requiring intravenous antibiotics at the time of initiating study treatment) and/or detectable viral infection.
  • Have received treatment with a prior cyclin-dependent kinase (CDK4) and CDK 6 inhibitor.
  • Have a preexisting chronic condition resulting in persistent diarrhea.
  • Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Tamoxifen

    Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Tamoxifen

  • Experimental
    Abemaciclib

    Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib + Prophylactic Loperamide

    Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Prophylactic Loperamide

Interventions

  • Administered orally

    Also known as: LY2835219

  • Administered orally

  • DrugProphylactic Loperamide

    Administered orally

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression-free survival time was measured from the date of randomization to the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.

    Time frame: Baseline to Objective Disease Progression or Death from Any Cause (Up to 21 Months)

Secondary outcomes

  1. Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

    Objective response rate was defined as the percentage of participants with CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD (longest diameter) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Baseline to Objective Disease Progression (Up to 21 Months)

  2. Duration of Response (DoR)

    DoR is defined as the time from the date of first evidence of a CR or PR to the date of objective progression or death from any cause, whichever is earlier as defined by Recist v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 21 Months)

  3. Overall Survival (OS)

    Time frame: Baseline to Death from Any Cause (Approximately 36 Months)

  4. Pharmacokinetics (PK): Mean Single Dose Concentration of Abemaciclib and Its Metabolites

    Mean single dose concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported.

    Time frame: Cycle (C) 1 Day (D) 1 post dose

  5. Pharmacokinetics (PK): Steady State Concentration of Abemaciclib and Its Metabolites

    Mean steady state concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported. C=Cycle D= Day

    Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose

  6. PK: Mean Single Dose Concentration of Tamoxifen and Endoxifen

    Mean single dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.

    Time frame: Cycle 1 Day 1 post dose

  7. PK: Multiple Dose Concentration of Tamoxifen and Endoxifen

    Mean multiple dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.

    Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose

  8. Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.

    Time frame: Baseline, 21 Months

  9. Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

    mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes.

    Time frame: Baseline, 21 Months

07

Results

Posted Jul 12, 2019

Participant flow

Participant flow — Overall Study
Milestone150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Started787977
Received at least one dose of study drug787977
Completed213030
Not completed574947
Withdrew: Withdrawal by subject854
Withdrew: Lost to follow-up122
Withdrew: On study treatment/follow-up484241

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression-free survival time was measured from the date of randomization to the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause, whichever occurred first. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.

Time frame:
Baseline to Objective Disease Progression or Death from Any Cause (Up to 21 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
Months150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Progression Free Survival (PFS)9.07 (6.90 to 10.95)6.48 (4.77 to 9.21)7.43 (5.42 to 9.17)
Statistical analysis
  • 150mg Abemaciclib + 20mg Tamoxifen vs 200mg Abemaciclib + 2mg Prophylactic Loperamide · Log Rank · p = 0.2930 (Two-sided P-value.)Stratified by the randomization factors of presence of liver metastases and prior use of Tamoxifen in the advanced/metastatic setting.
  • 150mg Abemaciclib vs 200mg Abemaciclib + 2mg Prophylactic Loperamide · Log Rank · Hazard ratio (hr): 1.045 · 95% CI 0.711 to 1.535Stratified by the randomization factors of presence of liver metastases and prior use of Tamoxifen in the advanced/metastatic setting.
SecondaryObjective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

Objective response rate was defined as the percentage of participants with CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD (longest diameter) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Baseline to Objective Disease Progression (Up to 21 Months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
Percentage of participants150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)34.6 (24.1 to 45.2)24.1 (14.6 to 33.5)32.5 (22 to 42.9)
SecondaryDuration of Response (DoR)

DoR is defined as the time from the date of first evidence of a CR or PR to the date of objective progression or death from any cause, whichever is earlier as defined by Recist v1.1. CR was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Up to 21 Months)
Reported as:
Median · Months
Duration of Response (DoR)
Months150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Duration of Response (DoR)7.40 (3.88 to 9.27)9.21 (3.72 to NA)7.46 (5.56 to 10.92)
SecondaryOverall Survival (OS)
Time frame:
Baseline to Death from Any Cause (Approximately 36 Months)

Results for this outcome have not been posted.

SecondaryPharmacokinetics (PK): Mean Single Dose Concentration of Abemaciclib and Its Metabolites

Mean single dose concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported.

Time frame:
Cycle (C) 1 Day (D) 1 post dose
Reported as:
Geometric mean · Nanogram per Millilitre (ng/mL)
Pharmacokinetics (PK): Mean Single Dose Concentration of Abemaciclib and Its Metabolites
Nanogram per Millilitre (ng/mL)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Abemaciclib (C1D1)10.9 ± 2313.05 ± 95.48.59 ± 440
M2 (C1D1)6.05 ± 1232.14 ± 60.16.85 ± 237
M20 (C1D1)6.50 ± 1322.54 ± 54.57.91 ± 220
SecondaryPharmacokinetics (PK): Steady State Concentration of Abemaciclib and Its Metabolites

Mean steady state concentrations of Abemaciclib and its metabolites (M2 \& M20) are reported. C=Cycle D= Day

Time frame:
Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose
Reported as:
Geometric mean · Nanogram per Millilitre (ng/mL)
Pharmacokinetics (PK): Steady State Concentration of Abemaciclib and Its Metabolites
Nanogram per Millilitre (ng/mL)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Abemaciclib (C1D15)214 ± 66.4256 ± 58.8314 ± 74.3
M2 (C1D15)96.5 ± 53.9108 ± 45.6147 ± 47.1
M20 (C1D15)180 ± 51.1199 ± 41.0251 ± 48.5
Abemaciclib (C2D1)98.9 ± 196182 ± 129220 ± 154
M2 (C2D1)56.1 ± 88.085.4 ± 62.1105 ± 98.5
M20 (C2D1)100 ± 103149 ± 78.9164 ± 171
Abemaciclib (C2D15)135 ± 115157 ± 173175 ± 136
M2 (C2D15)62.3 ± 79.071.7 ± 97.995.4 ± 73.9
M20 (C2D15)120 ± 76.2128 ± 121154 ± 101
Abemaciclib (C3D1)125 ± 64.3177 ± 42.0207 ± 49
M2 (C3D1)60.6 ± 39.678.4 ± 38.295.8 ± 44.2
M20 (C3D1)109 ± 39.4146 ± 37.7171 ± 36.6
SecondaryPK: Mean Single Dose Concentration of Tamoxifen and Endoxifen

Mean single dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.

Time frame:
Cycle 1 Day 1 post dose
Reported as:
Geometric mean · ng/mL
PK: Mean Single Dose Concentration of Tamoxifen and Endoxifen
ng/mL150mg Abemaciclib + 20mg Tamoxifen
Tamoxifen (C1D1)7.47 ± 116
Endoxifen (C1D1)NA ± NA
SecondaryPK: Multiple Dose Concentration of Tamoxifen and Endoxifen

Mean multiple dose concentrations of Tamoxifen and its metabolite (Endoxifen) were reported.

Time frame:
Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1 post dose
Reported as:
Geometric mean · ng/mL
PK: Multiple Dose Concentration of Tamoxifen and Endoxifen
ng/mL150mg Abemaciclib + 20mg Tamoxifen
Tamoxifen (C1D15)84.5 ± 41.6
Endoxifen (C1D15)4.76 ± 99.7
Tamoxifen (C2D1)98.7 ± 50.2
Endoxifen (C2D1)7.41 ± 89.5
Tamoxifen (C2D15)109 ± 51.9
Endoxifen (C2D15)9.17 ± 73.7
Tamoxifen (C3D1)112 ± 60.2
Endoxifen (C3D1)10.3 ± 84.8
SecondaryChange From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.

Time frame:
Baseline, 21 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
score on a scale150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Global Health Status1.56 ± 1.834.56 ± 1.90-2.77 ± 1.91
Functional Scales (Physical Functioning)-2.01 ± 1.59-1.05 ± 1.68-2.65 ± 1.68
Functional Scales (Role Functioning)-0.44 ± 2.18-3.95 ± 2.30-5.87 ± 2.29
Functional Scales (Emotional Functioning)4.40 ± 1.882.58 ± 1.951.86 ± 1.95
Functional Scale (Cognitive Functioning)0.14 ± 1.37-1.31 ± 1.44-2.39 ± 1.43
Functional Scales (Social Functioning)3.23 ± 2.08-0.53 ± 2.16-0.94 ± 2.16
Symptom Scales (Fatigue)2.39 ± 2.052.77 ± 2.154.0 ± 2.16
Symptom Scales (Nausea and Vomiting)5.59 ± 1.635.30 ± 1.735.09 ± 1.71
Symptom Scales (Pain)-3.09 ± 2.20-1.43 ± 2.30-2.01 ± 2.29
Symptom Scales (Dyspnoea)4.21 ± 1.79-3.49 ± 1.89-2.0 ± 1.87
Symptom Scales (Insomnia)-5.02 ± 2.21-3.43 ± 2.36-2.98 ± 2.35
Symptom Scales (Appetite Loss)5.82 ± 2.381.87 ± 2.507.76 ± 2.50
Symptom Scales (Constipation)-0.28 ± 1.57-6.29 ± 1.710.08 ± 1.67
Symptom Scales (Diarrhoea)13.31 ± 1.9720.17 ± 2.1017.43 ± 2.09
Symptom Scales (Functional Difficulties)-7.56 ± 2.00-3.81 ± 2.08-0.09 ± 2.07
SecondaryChange From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours and typical completion time for this instrument is less than 5 minutes.

Time frame:
Baseline, 21 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
score on a scale150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
Pain at its Worst in Last 24 Hours-0.53 ± 0.20-0.43 ± 0.21-0.43 ± 0.21
Pain at its Least in Last 24 Hours-0.09 ± 0.15-0.01 ± 0.160.14 ± 0.16
Pain on the Average-0.34 ± 0.16-0.20 ± 0.17-0.11 ± 0.17
Pain Right Now-0.28 ± 0.17-0.18 ± 0.17-0.04 ± 0.17
Mean Interference Score-0.09 ± 0.180.03 ± 0.180.16 ± 0.18

Adverse events

Collected over Up to 21 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150mg Abemaciclib + 20mg Tamoxifen18/78 (23.1%)16/78 (20.5%)73/78 (93.6%)
150mg Abemaciclib28/79 (35.4%)16/79 (20.3%)77/79 (97.5%)
200mg Abemaciclib + 2mg Prophylactic Loperamide29/77 (37.7%)21/77 (27.3%)75/77 (97.4%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
Event150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
LeukopeniaBlood and lymphatic system disorders0/783/790/77
NauseaGastrointestinal disorders0/781/792/77
VomitingGastrointestinal disorders1/781/792/77
AstheniaGeneral disorders2/780/791/77
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/782/791/77
NeutropeniaBlood and lymphatic system disorders0/782/790/77
ThrombocytopeniaBlood and lymphatic system disorders0/782/790/77
PyrexiaGeneral disorders1/782/791/77
DyspnoeaRespiratory, thoracic and mediastinal disorders1/782/790/77
Disseminated intravascular coagulationBlood and lymphatic system disorders1/780/791/77
Most frequent other events
Showing 10 of 60
Most frequent other events
Event150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic Loperamide
DiarrhoeaGastrointestinal disorders41/7853/7947/77
NauseaGastrointestinal disorders24/7826/7933/77
AnaemiaBlood and lymphatic system disorders30/7824/7931/77
ConstipationGastrointestinal disorders10/789/7925/77
Neutrophil count decreasedInvestigations11/7821/7922/77
Platelet count decreasedInvestigations8/789/7922/77
FatigueGeneral disorders22/7817/7921/77
NeutropeniaBlood and lymphatic system disorders21/7820/7918/77
VomitingGastrointestinal disorders14/7820/7920/77
Decreased appetiteMetabolism and nutrition disorders20/7812/7917/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic LoperamideTotal
Mean54.28 ± 12.4756.18 ± 12.2455.86 ± 11.0355.44 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic LoperamideTotal
Female787977234
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic LoperamideTotal
Hispanic or Latino16202157
Not Hispanic or Latino554546146
Unknown or Not Reported7141031
Race (NIH/OMB)
Race (NIH/OMB)(Participants)150mg Abemaciclib + 20mg Tamoxifen150mg Abemaciclib200mg Abemaciclib + 2mg Prophylactic LoperamideTotal
American Indian or Alaska Native43411
Asian861024
Native Hawaiian or Other Pacific Islander0000
Black or African American2125
White636460187
More than one race0101
Unknown or Not Reported1416
08

Study locations

59 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • University of Wisconsin Clinical Research Center
    Madison, Wisconsin 53705, United States
  • CENIT Centro de Neurociencias, Investigación y Tratamiento
    CABA, Buenos Aires C1125ABD, Argentina
  • Fundacion Ars Medica
    San Salvador de Jujuy, Jujuy Province Y4600APW, Argentina
  • Clinica Viedma
    Viedma, Río Negro Province R8500ACE, Argentina
  • Instituto de Oncología de Rosario
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Centro Para la Atención Integral del Paciente Oncologico (CAIPO)
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Sanatorio Parque
    Salta, 4400, Argentina
  • Medizinische Universitaet Graz
    Graz, Styria 8036, Austria
  • Universitätsklinik Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • AKH
    Vienna, 1090, Austria
  • Universitair Ziekenhuis Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
  • VITAZ
    Sint-Niklaas, Oost-Vlaanderen 9100, Belgium
  • Grand Hopital de Charleroi-Site Notre-Dame
    Charleroi, 6000, Belgium
  • Centre Hospitalier Universitaire Sart Tilman
    Liège, 4000, Belgium
  • Hospital São Lucas - PUCRS - ONCOLOGY
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784400, Brazil
  • Icesp - Instituto Do Câncer Do Estado de São Paulo
    São Paulo, 01246000, Brazil
  • Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária LTDA
    São Paulo, 01317-000, Brazil
  • Masarykuv onkologicky ustav
    Brno, Czech Republic 656 53, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Fakultni Poliklinika VFN
    Prague, 128 08, Czechia
  • Fakultni Nemocnice v Motole
    Prague, 150 06, Czechia
  • Thomayerova nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • Centre Oscar Lambret
    Lille, Hauts-de-France 59020, France
  • Institut Paoli-Calmettes
    Marseille, Provence-Alpes-Côte d'Azur Region 13273, France
  • Universitätsklinikum Ulm
    Ulm, Baden-Wurttemberg 89081, Germany
  • Kath. Marienkrankenhaus gGmbH
    Hamburg, 22087, Germany
  • Polic.Umberto I -Univ. La Sapienza
    Roma, Rome 00161, Italy
  • Ospedale Sacro Cuore Don G. Calabria
    Negrar, Verona 37024, Italy
  • Ospedale Bellaria - Azienda USL di Bologna
    Bologna, 40139, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Naples, 80131, Italy
  • Neurociencias Estudios Clinicos
    Culiacán, Sinaloa 80020, Mexico
  • Centro Hemato Oncologico Privado
    San Bernardino, Toluca 50080, Mexico
  • Grupo Medico Camino Sc
    Mexico City, 03310, Mexico
  • Oaxaca Site Management Organization
    Oaxaca City, 68000, Mexico
  • Republic Oncology Dispensary of MoH of Republic Tatarstan
    Kazan', 420029, Russia
  • St-Petersburg scientifical practical center of specialized medical care
    Saint Petersburg, 197758, Russia
  • Saint-Petersburg city clinical oncology dispensary
    Saint Petersburg, 198255, Russia
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad de 28034, Spain
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 235, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Chang Gung Memorial Hospital - Linkou
    Taoyuan City, 33305, Taiwan
  • Erciyes University Faculty of Medicine
    Kayseri, Melikgazi 38039, Turkey (Türkiye)
  • Medipol Mega University Hospital
    Istanbul, Turkey 34214, Turkey (Türkiye)
  • Baskent University Dr. Turgut Noyan Research and Training Center
    Adana, 1250, Turkey (Türkiye)
  • Hacettepe University Faculty of Medicine
    Ankara, 06100, Turkey (Türkiye)
  • Marmara University Medical Faculty
    Istanbul, 34668, Turkey (Türkiye)
09

References and documents

Publications

  • Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Zhang W, Chen Y, Martin M. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. Breast Cancer Res Treat. 2022 Aug;195(1):55-64. doi: 10.1007/s10549-022-06662-9. Epub 2022 Jul 12. PubMed 35829935 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2018, 21 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 21 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2016
First posted
Apr 21, 2016
StartActual
Sep 14, 2016
Primary completionActual
Jun 15, 2018
CompletionActual
Sep 9, 2026was Dec 2026
Results first posted
Jul 12, 2019
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
Oct 16, 2026
Study completion
Dec 2026→Sep 9, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Medipol Mega University Hospital · Istanbul, Turkey (Türkiye)
    Study completion Dec 2026→Sep 9, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02747004
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
Sep 14, 2016
Primary completion
Jun 15, 2018
Completion
Sep 9, 2026
Results posted
Jul 12, 2019
Last update
Oct 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion